Financial news for CLRB dated on 2020-06-10: 34 Stocks Moving in Wednesday's Pre-Market Session

Financial news for CLRB dated on 2020-06-10: Aigh Capital Management, Llc. Reports A Passive Stake Of 6.52% In Cellectar Biosciences As Of June 3

Financial news for CLRB dated on 2020-06-04: The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic

Financial news for CLRB dated on 2020-06-04: 85 Biggest Movers From Yesterday

Financial news for CLRB dated on 2020-06-03: 58 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLRB dated on 2020-06-03: Stocks That Hit 52-Week Lows On Wednesday

Financial news for CLRB dated on 2020-06-03: Cellectar Biosciences Announces Pricing of \$20 Million Underwritten Public Offering At \$1.15 Per Share

Financial news for CLRB dated on 2020-06-03: 31 Stocks Moving in Wednesday's Pre-Market Session

Financial news for CLRB dated on 2020-06-01: Cellectar Granted SME Status By European Medicines Agency

Financial news for CLRB dated on 2020-05-28: 70 Biggest Movers From Yesterday

Financial news for CLRB dated on 2020-05-27: 58 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLRB dated on 2020-05-27: 33 Stocks Moving in Wednesday's Pre-Market Session

Financial news for CLRB dated on 2020-05-27: 96 Biggest Movers From Yesterday

Financial news for CLRB dated on 2020-05-26: 61 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLRB dated on 2020-05-26: P/E Ratio Insights for Cellectar Biosciences

Financial news for CLRB dated on 2020-05-26: Cellectar Biosciences shares are trading higher after the company reported it received FDA fast track designation for CLR 131 in Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia.

Financial news for CLRB dated on 2020-05-26: Cellectar Receives FDA Fast Track Designation For CLR 131 In Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia

Financial news for CLRB dated on 2020-05-14: Cellectar Granted Composition Of Matter And Use Patent In Europe For CLR 131

Financial news for CLRB dated on 2020-05-07: Cellectar Biosciences Q1 EPS (0.420) Up From (0.760) YoY

Financial news for CLRB dated on 2020-04-08: Shares of several energy companies are trading higher amid hopes of output cuts by major oil producers Russia and Saudi Arabia to support prices.

Financial news for CLRB dated on 2020-03-09: Cellectar Biosciences Q4 EPS \$(0.33) Down From \$0.06 YoY

Financial news for CLRB dated on 2020-02-21: 95 Biggest Movers From Yesterday

Financial news for CLRB dated on 2020-02-20: 71 Stocks Moving In Thursday's Mid-Day Session

Financial news for CLRB dated on 2020-02-20: 78 Biggest Movers From Yesterday

Financial news for CLRB dated on 2020-02-19: 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLRB dated on 2020-02-19: The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

Financial news for CLRB dated on 2020-02-18: 35 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLRB dated on 2020-02-16: The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions

Financial news for CLRB dated on 2020-01-21: Roth Capital Assumes Cellectar Biosciences at Buy, Announces \$10 Price Target

Financial news for CLRB dated on 2019-12-30: 58 Biggest Movers From Friday

Financial news for CLRB dated on 2019-12-27: 60 Biggest Movers From Yesterday

Financial news for CLRB dated on 2019-12-23: Cellectar Biosciences Receives FDA Orphan Drug Designation For 18-(p-[1311]-iodophenyl)octadecyl phosphocholine

Financial news for CLRB dated on 2019-12-16: Cellectar Biosciences Announces a 30% Overall Response Rate in Patients Receiving a Single Dose of CLR 131 in the Phase 2 CLOVER-1 Study

Financial news for CLRB dated on 2019-12-09: Cellectar Biosciences Announces Presentation Of Fractionated Dosing Data Of CLR 131 In Relapsed Or Refractory Multiple Myeloma Patients

Financial news for CLRB dated on 2019-11-15: The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

Financial news for CLRB dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for CLRB dated on 2019-11-12: Cellectar Biosciences Q3 EPS (0.42) Up From (1.65) YoY

Financial news for CLRB dated on 2019-10-30: Cellectar Highlights Presentation Of New Phospholipid Drug Conjugate At AACR-NCI-EORTC Conference

Financial news for CLRB dated on 2019-09-30: Cellectar Presents Data From DLBCL Cohort Of Phase 2 CLOVER-1 Study at At European Society For Medical Oncology Congress

Financial news for CLRB dated on 2019-09-25: 23 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLRB dated on 2019-09-24: Cellectar Receives Orphan Drug Designation From The European Commission For CLR 131 In Multiple Myeloma

Financial news for CLRB dated on 2019-09-13: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for CLRB dated on 2019-09-13: Roth Capital Initiates Coverage On Cellectar Biosciences with Buy Rating, Announces \$11 Price Target

Financial news for CLRB dated on 2019-09-08: The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight

Financial news for CLRB dated on 2019-08-15: Cellectar Biosciences Names Dov Elefant CFO

Financial news for CLRB dated on 2019-08-12: Cellectar Biosciences Q2 EPS (0.46) Beats (0.69) Estimate

Financial news for CLRB dated on 2019-08-08: 50 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for CLRB dated on 2019-07-30: Benzinga's Top Upgrades, Downgrades For July 30, 2019

Financial news for CLRB dated on 2019-07-30: 42 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLRB dated on 2019-07-30: Brookline Capital Initiates Coverage On Cellectar Biosciences with Buy Rating, Announces \$6 Price Target

Financial news for CLRB dated on 2019-07-30: 45 Healthcare Stocks Moving In Monday's After-Market Session

Financial news for CLRB dated on 2019-07-09: Cellectar Biosciences shares are trading higher after the company received FDA fast track designation for CLR 131 in diffuse large B-Cell Lymphoma.

Financial news for CLRB dated on 2019-07-09: Cellectar Receives FDA Fast Track Designation For CLR 131 In Diffuse Large B-Cell Lymphoma

Financial news for CLRB dated on 2019-06-13: 50 Biggest Movers From Yesterday

Financial news for CLRB dated on 2019-06-12: 35 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLRB dated on 2019-06-12: Shares of several oil and gas companies are trading lower following negative oil price catalysts. EIA on Wednesday cut 2019 demand forecasts while there was a reported increase in crude inventories. US-China trade tensions have weighed on demand outlook.

Financial news for CLRB dated on 2019-06-05: The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache

Financial news for CLRB dated on 2019-05-29: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLRB dated on 2019-05-21: Cellectar Biosciences shares are trading higher after the company reported expansion of third cohort of phase 2 CLOVER-1 study of CLR 131.

Financial news for CLRB dated on 2019-05-21: Cellectar Biosciences Reports Expansion Of Third Cohort Of Phase 2 CLOVER-1 Study Of CLR 131

Financial news for CLRB dated on 2019-05-20: 60 Biggest Movers From Friday

Financial news for CLRB dated on 2019-05-17: 44 Stocks Moving In Friday's Mid-Day Session

Financial news for CLRB dated on 2019-05-17: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for CLRB dated on 2019-05-17: 63 Biggest Movers From Yesterday

Financial news for CLRB dated on 2019-05-16: A Look At Benzinga Pro's 10 Most-Searched Tickers For May 16, 2019

Financial news for CLRB dated on 2019-05-16: Mid-Afternoon Market Update: KEMET Jumps On Upbeat Q4 Results; EDAP Shares Plunge

Financial news for CLRB dated on 2019-05-16: 50 Stocks Moving In Thursday's Mid-Day Session

Financial news for CLRB dated on 2019-05-16: Mid-Day Market Update: Crude Oil Up Over 2%; Virtusa Shares Drop Following Downbeat Q4 Earnings

Financial news for CLRB dated on 2019-05-16: Mid-Morning Market Update: Markets Open Higher; Walmart Earnings Top Expectations

Financial news for CLRB dated on 2019-05-16: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Thur., May 16, 2019

Financial news for CLRB dated on 2019-05-16: Cellectar Biosciences Reports \$10M Financing: \$5M In Registered Direct Offering Of $\sim 1.982M$ Common Shares, \$5M Concurrent Private Placement Of 2.018M Common Shares

Financial news for CLRB dated on 2019-05-16: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for CLRB dated on 2019-05-16: 60 Biggest Movers From Yesterday

Financial news for CLRB dated on 2019-05-15: 44 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLRB dated on 2019-05-15: Mid-Morning Market Update: Markets Mostly Lower; Macy's Earnings Top Estimates

Financial news for CLRB dated on 2019-05-14: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tue., May 14, 2019

Financial news for CLRB dated on 2019-05-13: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for CLRB dated on 2019-05-13: Benzinga Pro's Top 8 Most-Searched Tickers For Morning of Mon., May 13, 2019

Financial news for CLRB dated on 2019-05-13: Cellectar Recieves FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma

Financial news for CLRB dated on 2019-05-09: Shares of several oil companies are

trading lower as oil prices fall. US-China trade concerns have caused concern over global oil demand outlook, outweighing the positive effect of falling US crude stockpiles.

Financial news for CLRB dated on 2019-05-06: Cellectar Biosciences Q1 EPS \$(0.76) Misses \$(0.74) Estimate

Financial news for CLRB dated on 2019-05-02: 5 Biotech Stocks With Near-Term Catalysts Ahead

Financial news for CLRB dated on 2019-05-02: H.C. Wainwright Initiates Coverage On Cellectar Biosciences, Inc. - Common Stock with Buy Rating, Announces \$4 Price Target

Financial news for CLRB dated on 2019-03-26: Shares of several oil companies are trading higher following a 2% climb in the price of crude oil due to investor sentiment that OPEC supply cuts and lower US inventory have outweighed concern for weaker demand.

Financial news for CLRB dated on 2019-03-21: 52 Biggest Movers From Yesterday

Financial news for CLRB dated on 2019-03-20: 41 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLRB dated on 2019-03-20: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Wed., Mar. 20, 2019

Financial news for CLRB dated on 2019-03-19: 45 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLRB dated on 2019-03-19: 45 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLRB dated on 2019-03-19: Cellectar Biosciences shares are trading higher after the FDA granted an exemption to the import alert for Cellectar's CLR 131 in pediatric and adolescent patients

Financial news for CLRB dated on 2019-03-19: FDA Grants Exemption To Import Alert For Cellectar's CLR 131 In Pediatric And Adolescent Patients

Financial news for CLRB dated on 2019-03-19: 60 Biggest Movers From Yesterday

Financial news for CLRB dated on 2019-03-08: 64 Biggest Movers From Yesterday

Financial news for CLRB dated on 2019-03-07: 51 Stocks Moving In Thursday's Mid-Day Session

Financial news for CLRB dated on 2019-03-07: Cellectar Shares Sharply Higher, Not Seeing Fundamental News; Co. Is Likely A Low-Float Play, Has 1.7M Shares In Float; Unknown Twitter Source Suggests Stock Is 'next direct sympathy of Bio-Path'; Benzinga Has Not Confirmed This Information

Financial news for CLRB dated on 2019-03-07: Cellectar Biosciences Shares Spike To Session High, Now Up 15%

Financial news for CLRB dated on 2019-03-05: The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings

Financial news for CLRB dated on 2019-02-26: 54 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLRB dated on 2019-02-26: Cellectar FY18 EPS \$(5.23) vs \$(10.70) In FY17

Financial news for CLRB dated on 2019-02-25: Cellectar Biosciences Reports Top-Line Response Rate Of 30% From R/R Multiple Myeloma Cohort In Ongoing Phase 2 Study Of CLR 131: 1 Patient Achieved Very Good PArtial Response, All Patients Showed At Least Stable Disease

Financial news for CLRB dated on 2019-01-07: Cellectar Reports Median Overall Survival Rate In Cohorts 1-4 Of Phase 1 Trial Of CLR131 In Multiple Myeloma; Median Overall Survival Of 22 Months Observed

Financial news for CLRB dated on 2019-01-07: Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

Financial news for CLRB dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for CLRB dated on 2018-12-20: Stocks Which Set New 52-Week Low

Yesterday, Tues., Dec. 20, 2018

Financial news for CLRB dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for CLRB dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for CLRB dated on 2018-12-11: Cellectar Biosciences shares are trading higher after the company was granted a Japanese patent for CLR 131 in breast, brain and other cancers including leukemia.

Financial news for CLRB dated on 2018-12-11: Cellectar Granted Japanese Patent For CLR 131 In Breast, Brain And Other Cancers Including Leukemia

Financial news for CLRB dated on 2018-12-04: Cellectar Initiates Cohort 6 Of Phase 1b Trial Evaluating CLR 131 In Relapsed/Refractory Multiple Myeloma

Financial news for CLRB dated on 2018-11-23: Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018

Financial news for CLRB dated on 2018-11-12: Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

Financial news for CLRB dated on 2018-10-08: 46 Biggest Movers From Friday

Financial news for CLRB dated on 2018-10-04: 5 Stocks Moving In Thursday's After-Hours Session

Financial news for CLRB dated on 2018-10-04: 55 Biggest Movers From Yesterday

Financial news for CLRB dated on 2018-10-03: 43 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLRB dated on 2018-10-03: 45 Biggest Movers From Yesterday

Financial news for CLRB dated on 2018-10-02: Mid-Morning Market Update: Markets Mostly Higher; PepsiCo Tops Q3 Estimates

Financial news for CLRB dated on 2018-10-02: UPDATE: Cellectar Results For CLR 131 Show Overall Survival At 19.4 Months

Financial news for CLRB dated on 2018-10-02: Cellectar Biosciences Offered Updates On Interim Overall Survival Data From Ongoing Phase 1b Trial Evaluating CLR 131 For Treatment Of Relapsed/Refractory Multiple Myeloma

Financial news for CLRB dated on 2018-09-28: 51 Biggest Movers From Yesterday

Financial news for CLRB dated on 2018-09-27: 36 Stocks Moving In Thursday's Mid-Day Session

Financial news for CLRB dated on 2018-09-27: 41 Biggest Movers From Yesterday

Financial news for CLRB dated on 2018-09-26: Cellectar Biosciences shares are up 9.5% to \$2.95; Shares continue to move higher after the company on Tuesday received FDA Orphan Drug Designation for its CLR 131 pediatric osteosarcoma treatment.

Financial news for CLRB dated on 2018-09-26: The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial

Financial news for CLRB dated on 2018-09-25: Cellectar's CLR 131 Receives FDA Orphan Drug Designation For Treatment Of Pediatric Osteosarcoma

Financial news for CLRB dated on 2018-09-24: Cellectar Biosciences Announces the FDA Has Initiated Talks with the Company to Potentially Exempt it From an Import Alert

Financial news for CLRB dated on 2018-09-21: 56 Biggest Movers From Yesterday

Financial news for CLRB dated on 2018-09-18: Stocks Which Set New 52-Week Low Yesterday, September 17th

Financial news for CLRB dated on 2018-09-17: Stocks Which Set New 52-Week Low Friday, September 14

Financial news for CLRB dated on 2018-09-17: Cellectar Biosciences shares are up 18.7% after the FDA granted Rare Pediatric Disease designation to the company's CLR 131 for the treatment of osteosarcoma, a form of pediatric cancer.

Financial news for CLRB dated on 2018-09-17: Cellectar Biosciences' CLR 131 Granted

Rare Pediatric Disease Designation

Financial news for CLRB dated on 2018-09-12: Stocks Which Set New 52-Week Low Yesterday, September 11th

Financial news for CLRB dated on 2018-09-11: The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces \$175M Offering, Leadership Transition At Insulet

Financial news for CLRB dated on 2018-09-10: Stocks Which Set New 52-Week Low Friday, September 7th

Financial news for CLRB dated on 2018-08-20: Cellectar Biosciences Announces 'Positive' Results from Cohort 5 of Phase 1b Trial

Financial news for CLRB dated on 2018-08-13: Benzinga Pro's Top 10 Most-Searched Tickers Monday, August 13th

Financial news for CLRB dated on 2018-08-13: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for CLRB dated on 2018-08-13: Benzinga Pro's 5 Stocks To Watch Today

Financial news for CLRB dated on 2018-08-13: Cellectar's CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing's Sarcoma

Financial news for CLRB dated on 2018-08-10: Stocks Which Set New 52-Week Low Yesterday, August 9th

Financial news for CLRB dated on 2018-08-10: Cellectar Biosciences Q2 EPS (1.69) Beats (2.10) Estimate

Financial news for CLRB dated on 2018-08-09: Stocks Which Set New 52-Week Low Yesterday, August 8th

Financial news for CLRB dated on 2018-08-02: Stocks Which Set New 52-Week Low Yesterday, August 1st

Financial news for CLRB dated on 2018-08-01: Cellectar Biosciences Up 12% After Announcement Co. Will Partner With Orano Med To Create Novel Phospholipid Drug Conjugates For Oncologic Therapy

Financial news for CLRB dated on 2018-07-30: Stocks Which Set New 52-Week Low Friday, July 27

Financial news for CLRB dated on 2018-07-30: 62 Biggest Movers From Friday

Financial news for CLRB dated on 2018-07-27: Benzinga's Biggest Movers For The Week Of July 23, 2018

Financial news for CLRB dated on 2018-07-27: Mid-Afternoon Market Update: NASDAQ Down 1.7%; World Fuel Services Shares Gain Following Upbeat Q2 Results

Financial news for CLRB dated on 2018-07-27: 55 Stocks Moving In Friday's Mid-Day Session

Financial news for CLRB dated on 2018-07-27: Mid-Day Market Update: Essendant Rises After Q2 Results; Tonix Pharmaceuticals Shares Plunge

Financial news for CLRB dated on 2018-07-27: Stocks Which Set New 52-Week Low Yesterday, July 26th:

Financial news for CLRB dated on 2018-07-27: Mid-Morning Market Update: Markets Mostly Lower; Twitter Shares Fall Following Q2 Results

Financial news for CLRB dated on 2018-07-27: Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter

Financial news for CLRB dated on 2018-07-27: UPDATE: Cellectar Biosciences Prices Offering At 4/Share

Financial news for CLRB dated on 2018-07-27: Cellectar Biosciences Prices Public Offering For Gross Proceeds Of \$14.4M

Financial news for CLRB dated on 2018-07-27: 36 Stocks Moving In Friday's Pre-Market Session

Financial news for CLRB dated on 2018-07-26: 10 Stocks Moving In Thursday's After-Hours Session

Financial news for CLRB dated on 2018-07-26: Cellectar Resumes Trade, Now Up 4.87% At \$6.25/Share

Financial news for CLRB dated on 2018-07-26: BZ NOTE On Cellectar Price Action: Reminder This Has Been A Recent Low-Float Play, Has $\sim 1.7M$ Shares In Float

Financial news for CLRB dated on 2018-07-26: Cellectar Biosciences Shares Halted On Circuit Breaker Up 20%; Light Volume Of $\sim 11 \, \mathrm{K}$ Shares, Not Seeing News To Justify Spike Higher

Financial news for CLRB dated on 2018-07-23: 41 Biggest Movers From Friday

Financial news for CLRB dated on 2018-07-20: 31 Stocks Moving In Friday's Mid-Day Session

Financial news for CLRB dated on 2018-07-20: 50 Biggest Movers From Yesterday

Financial news for CLRB dated on 2018-07-19: 40 Stocks Moving In Thursday's Mid-Day Session

Financial news for CLRB dated on 2018-07-19: 51 Biggest Movers From Yesterday

Financial news for CLRB dated on 2018-07-18: Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Wed., Jul. 18, 2018

Financial news for CLRB dated on 2018-07-18: 42 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLRB dated on 2018-07-18: Cellectar Biosciences Shares Up 7.1% Premarket After Co. Announced Encouraging Results From CLR 131 Phase 2 Clinical Trial With Diffuse Large B-Cell Lymphoma Patients, Overall Response Rate Was 33% With Tumor Reductions Ranging From 60% To Over 90%

Financial news for CLRB dated on 2018-07-18: UPDATE: Cellectar Expands Cohort For CLR 131 To Added 30 Patients

Financial news for CLRB dated on 2018-07-18: Cellectar Biosciences Reports Phase 2 Interim Data From CLR 131 In Relapsed/Refractory DLBCL Patients: Showed 33% Overall Response Rate, 50% Clinical Benefit Response

Financial news for CLRB dated on 2018-07-17: Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Jul. 17, 2018

Financial news for CLRB dated on 2018-07-17: 28 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLRB dated on 2018-07-17: Mid-Day Market Update: Avid Bioservices Surges Following Earnings Beat; Netflix Shares Plunge

Financial news for CLRB dated on 2018-07-17: Cellectar Shares Climb After Strong Trial Response For Rare Blood Cancer Drug

Financial news for CLRB dated on 2018-07-17: Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Earnings Top Expectations

Financial news for CLRB dated on 2018-07-17: Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study

Financial news for CLRB dated on 2018-07-16: A Peek Into The Markets: US Stock Futures Edge Higher, Bank of America Profit Tops Views

Financial news for CLRB dated on 2018-07-16: 6 Stocks To Watch For July 16, 2018

Financial news for CLRB dated on 2018-07-13: Cellectar Announces 1-for-10 Reverse Stock Split

Financial news for CLRB dated on 2018-07-10: 30 Biggest Movers From Yesterday

Financial news for CLRB dated on 2018-07-09: 28 Stocks Moving In Monday's Mid-Day Session

Financial news for CLRB dated on 2018-07-09: Cellectar's CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing's Sarcoma

Financial news for CLRB dated on 2018-07-03: Benzinga's Daily Biotech Pulse: Titan's Parkinson's Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32% Premium

Financial news for CLRB dated on 2018-06-28: Cellectar Announces Expansion of Diffuse

Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial

Financial news for CLRB dated on 2018-06-27: Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading

Financial news for CLRB dated on 2018-06-26: Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results

Financial news for CLRB dated on 2018-06-22: Benzinga's Daily Biotech Pulse: FDA Greenlights Tandem Diabetes' Insulin Pump, More IPOs On Tap

Financial news for CLRB dated on 2018-06-21: Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street

Financial news for CLRB dated on 2018-06-07: Cellectar Granted U.S. Patent For Treatment Of Various Cancers And Cancer Stem Cells With CLR 131

Financial news for CLRB dated on 2018-06-07: 40 Biggest Movers From Yesterday

Financial news for CLRB dated on 2018-06-06: 28 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLRB dated on 2018-06-06: Mid-Morning Market Update: Markets Mostly Higher; Signet Jewelers Earnings Top Estimates

Financial news for CLRB dated on 2018-06-06: Cellectar Biosciences Shares Up 43.5% Premarket After FDA Granted Rare Pediatric Disease Designation To Co.'s CLR 131 For Rhabdomyosarcoma

Financial news for CLRB dated on 2018-06-06: FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences' CLR 131 for the Treatment of Rhabdomyosarcoma

Financial news for CLRB dated on 2018-05-25: Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

Financial news for CLRB dated on 2018-05-24: Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

Financial news for CLRB dated on 2018-05-23: Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

Financial news for CLRB dated on 2018-05-11: Cellectar Biosciences Q1 EPS (0.21) Misses (0.20) Estimate

Financial news for CLRB dated on 2018-05-09: Cellectar Biosciences Granted FDA Orphan Drug Designation For CLR 131

Financial news for CLRB dated on 2018-05-02: Cellectar Biosciences Reports Received Rare Pediatric Disease Designation For CLR 131 To Treat Neuroblastoma

Financial news for CLRB dated on 2018-04-04: Cellectar Biosciences Names Brian Posner CFO

Financial news for CLRB dated on 2018-04-03: Cellectar Reports Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma

Financial news for CLRB dated on 2018-03-27: Cellectar Granted A US Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles

Financial news for CLRB dated on 2018-03-21: Cellectar Biosciences Reorts FY17 EPS \$(1.07) Misses \$(0.96) Est.

Financial news for CLRB dated on 2018-03-21: Earnings Scheduled For March 21, 2018

Financial news for CLRB dated on 2018-03-19: Cellectar Biosciences Shares Up 2.5% For Session, Down 22% From Pre-Market Highs; FDA Late Fri. Granted CLR 131 Orphan Drug Status For Neuroblastoma

Financial news for CLRB dated on 2018-03-19: Benzinga Pro's 5 Stocks To Watch Today

Financial news for CLRB dated on 2018-03-19: Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma

Financial news for CLRB dated on 2018-03-16: FDA.gov Site Shows Cellectar Biosciences With Orphan Drug Desingation For Neuroblastoma Treatment

Financial news for CLRB dated on 2018-02-07: Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma

Financial news for CLRB dated on 2018-01-29: Cellectar Starts DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers

Financial news for CLRB dated on 2017-12-14: Cellectar Biosciences Reports Filing Of IND For Phase 1 Trial Of CLR 131 In Pediatric Cancers

Financial news for CLRB dated on 2017-12-06: Cellectar Announces Expansion To 40 Patients of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131

Financial news for CLRB dated on 2017-11-09: Cellectar Biosciences Reports Q3 EPS \$(0.26) vs \$(0.25) Est.

Financial news for CLRB dated on 2017-10-24: Cellectar Biosciences Reports Introduction Of Multi-Dose Regimen In 5th Cohort Of Phase 1 Trial OF CLR 131 In Multiple Myeloma

Financial news for CLRB dated on 2017-10-17: Cellectar Biosciences Receives Japanese Patents for CLR 131 and CLR 125

Financial news for CLRB dated on 2017-10-10: CORRECTION: Cellectar Biosciences Reports \$7.76M Registered Direct ATM Offering

Financial news for CLRB dated on 2017-10-10: Cellectar Biosciences Reports \$7.76M Registered Direct ATM Offering

Financial news for CLRB dated on 2017-10-10: Cellectar Biosciences Reports Extended Collaboration Deal With Pierre Fabre For Development Of New Phospholipid Drug Conjugates

Financial news for CLRB dated on 2017-09-21: Cellectar Reports Strategic Collab. With Onconova Therapeutics Related To Developing Of New Phospholipid Drug Conjugates

Financial news for CLRB dated on 2017-08-22: Cellectar Biosciences Reports PDC Platform 'has generated numerous PDC molecules that show significant improved pharmacologic activity versus the payload molecule alone'

Financial news for CLRB dated on 2017-08-14: Cellectar Biosciences Reports Q2 EPS \$(0.23) vs. \$(0.24) Est.

Financial news for CLRB dated on 2017-08-08: Cellectar Biosciences Reports CLR 131 Achieved Overall Survival Of 22+ Months In Advanced Multiple Myeloma Patients

Financial news for CLRB dated on 2017-08-01: Cellectar Biosciences Signs Partnership with Avicenna Oncology to Develop New PDCs for Solid Tumors

Financial news for CLRB dated on 2017-06-05: S-3 from Cellectar Biosciences Shows Registration for \$50M Mixed Securities Shelf Offering

Financial news for CLRB dated on 2017-05-18: Cellectar Biosciences Offers 3 Abstracts on Dosing Regimens of CLR 131, Discusses Study Setup

Financial news for CLRB dated on 2017-05-11: Cellectar Biosciences Reports Q1 EPS \$(0.24) vs \$(0.23) Est.

Financial news for CLRB dated on 2017-04-25: Cellectar Biosciences Reports Received Added US Patents for PDC Optical Agents in Detection of Multiple Cancers

Financial news for CLRB dated on 2017-04-18: Cellectar Biosciences Receives Japanese Patent for CLR 131, CLR 125 For Cancer Stem Cell Treatment

Financial news for CLRB dated on 2017-04-12: Cellectar Biosciences Names John Friend Chief Medical Officer

Financial news for CLRB dated on 2017-03-30: Cellectar Biosciences Reports Initiation of Phase II Study of CLR 131

Financial news for CLRB dated on 2017-03-21: Cellectar Biosciences Reports Patent Grant for PET Imaging PDC

Financial news for CLRB dated on 2017-03-15: Cellectar Reports FY16 EPS (1.36) vs (0.54) Est.

Financial news for CLRB dated on 2017-02-27: 15 Biggest Mid-Day Gainers For Monday

Financial news for CLRB dated on 2017-02-27: Mid-Day Market Update: Gogo Surges After Strong Q4 Results; AmTrust Financial Shares Slide

Financial news for CLRB dated on 2017-02-27: Mid-Morning Market Update: Markets Edge

Lower; Sotheby's Beats Q4 Views

Financial news for CLRB dated on 2017-02-23: Cellectar Biosciences Falls to Low of \$1.99 on Volume

Financial news for CLRB dated on 2017-02-22: Cellectar Biosciences Begins Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma

Financial news for CLRB dated on 2017-01-24: 20 Biggest Mid-Day Gainers For Tuesday

Financial news for CLRB dated on 2017-01-24: Mid-Morning Market Update: Markets Open Higher; Verizon Earnings Miss Expectations

Financial news for CLRB dated on 2017-01-24: Cellectar Biosciences Reports Additional US Patent Granted for CLR 131 and CLR 125 in a Broad Range of Solid Tumors

Financial news for CLRB dated on 2016-12-21: Ladenburg Thalmann Initiates Coverage On Cellectar Biosciences at Buy, Announces \$2.70 Target

Financial news for CLRB dated on 2016-12-20: Cellectar Biosciences Announces US and Japanese Patent Allowances for Diagnostic and Optical Imaging PDCs

Financial news for CLRB dated on 2016-12-14: Cellectar Biosciences Reports USPTO Grants Patent Allowances for Radiotherapeutic PDCs for A Variety of Solid Tumor Types

Financial news for CLRB dated on 2016-12-12: Cellectar Biosciences Announces USPTO Grants Patent for Paclitaxel PDC; Provides Additional Patent Protection for Select Solid Tumors Through 2035

Financial news for CLRB dated on 2016-11-28: Cellectar Biosciences Announces Partnership with Radiopharmaceutical Specialists, CPDC, to Establish Manufacturing Capacity in Anticipation of CLR 131 Pivotal Trial and Commercial Production

Financial news for CLRB dated on 2016-11-23: Mid-Afternoon Market Update: Caleres Rises On Earnings Beat; Juno Therapeutics Shares Slide

Financial news for CLRB dated on 2016-11-23: A Tough Day For Some Biotech Bulls

Financial news for CLRB dated on 2016-11-23: 18 Biggest Mid-Day Losers For Wednesday

Financial news for CLRB dated on 2016-11-23: Mid-Day Market Update: Eli Lilly Tumbles After Alzheimer's Study Fails To Meet Goals; Euroseas Shares Rise

Financial news for CLRB dated on 2016-11-23: Mid-Morning Market Update: Markets Mostly Lower; Deere Tops Q4 Views

Financial news for CLRB dated on 2016-11-23: Cellectar Biosciences Announces Pricing of \$8,000,000 Public Offering

Financial news for CLRB dated on 2016-11-15: Cellectar Biosciences Spiked 30% On Phase 2 INC Contract

Financial news for CLRB dated on 2016-11-15: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for CLRB dated on 2016-11-15: Cellectar Biosciences Announces INC Research as the CRO for the Phase II Trial of CLR 131 in Hematologic Malignancies; \$2M NCI Grant Covers Half of Study Cost, with Potential Option to Pursue Additional \$3M for Pivotal Trial

Financial news for CLRB dated on 2016-11-11: Earnings Scheduled For November 11, 2016

Financial news for CLRB dated on 2016-10-31: UPDATE: Cellectar Sees Prelim. Data on CLR 131 as Early as 2H'17

Financial news for CLRB dated on 2016-10-31: Cellectar Biosciences Reports Design for NCI-Supported Phase II Study of CLR 131 in Multiple Myeloma, Other Hematologic Malignancies; Co. Accelerates Guidance for Initiation of Trial

Financial news for CLRB dated on 2016-10-06: Cellectar Biosciences Announces Enrollment of First Patient into Third Cohort of Its Phase I Clinical Study of CLR 131 in Multiple Myeloma

Financial news for CLRB dated on 2016-10-04: Cellectar Biosciences Announces USPTO Issues Formal Patent Allowance for CLR 1603

Financial news for CLRB dated on 2016-09-29: Cellectar Biosciences Reports New Positive Data from Phase I Clinical Study of CLR 131 in Multiple Myeloma

Financial news for CLRB dated on 2016-09-12: Cellectar Biosciences Announces Lead

Compound CLR 131 To Be Studied In Head and Neck Cancer in \$12M University of Wisconsin SPORE Grant

Financial news for CLRB dated on 2016-08-11: Cellectar Biosciences Reports Q2 R&D Expenses \$1M, Cash, Cash Equivalents of \$7.9M at End of Qtr.

Financial news for CLRB dated on 2016-06-23: Mid-Morning Market Update: Markets Open Higher; BlackBerry Profit Tops Views

Financial news for CLRB dated on 2016-06-23: Cellectar Biosciences Reports Results of NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer

Financial news for CLRB dated on 2016-06-15: 10 Biggest Mid-Day Gainers For Wednesday

Financial news for CLRB dated on 2016-06-15: Mid-Day Market Update: Patriot National Climbs Following Offer from Ebix; Carbylan Therapeutics Shares Tumble

Financial news for CLRB dated on 2016-06-15: Mid-Morning Market Update: Markets Open Higher; Aegerion Pharmaceuticals And QLT Agree To Merge

Financial news for CLRB dated on 2016-06-15: Cellectar Biosciences Reports Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in Tumor Targeting to Free Paclitaxel, Says CLR 1602 Tumor Selectivity ~30 Times Greater Than Paclitaxel Alone

Financial news for CLRB dated on 2016-06-02: Richard Hertzberg Reports 6.638% Stake in Cellectar Biosciences in 13G

Financial news for CLRB dated on 2016-05-31: Cellectar Biosciences Announces USPTO Issues Patent for its Radiotherapeutic PDC Portfolio

Financial news for CLRB dated on 2016-05-25: Mid-Morning Market Update: Markets Open Higher; Express Earnings Miss Views

Financial news for CLRB dated on 2016-05-25: Cellectar Biosciences Issues U.S. Patent for New PDC with Paclitaxel. Covers CLR 1603

Financial news for CLRB dated on 2016-05-24: Top 4 Pre-Market Losers

Financial news for CLRB dated on 2016-05-20: Mid-Afternoon Market Update: New York & Company Falls On Weak Results; InterOil Shares Spike Higher

Financial news for CLRB dated on 2016-05-20: Flavor Of The Day: Cellectar Biosciences

Financial news for CLRB dated on 2016-05-20: Cellectar Biosciences Jumps 200% After Getting Patent Identification Numbers For Cancer-Targeting Drug Vehicles

Financial news for CLRB dated on 2016-05-20: 10 Biggest Mid-Day Gainers For Friday

Financial news for CLRB dated on 2016-05-20: Cellectar Reports Patent App for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO

Financial news for CLRB dated on 2016-04-20: Cellectar Biosciences Closes \$8 Million Public Issue

Financial news for CLRB dated on 2016-04-15: Collectar Biosciences Prices \$7.0 Million Public Issue

Financial news for CLRB dated on 2016-04-15: Stocks Hitting 52-Week Lows

Financial news for CLRB dated on 2016-04-15: Mid-Morning Market Update: Markets Edge Lower; Citigroup Profit Tops Views

Financial news for CLRB dated on 2016-04-15: Cellectar Biosciences Prices Offer at \$2.13/Share for Gross Proceeds ~\$7M

Financial news for CLRB dated on 2016-03-30: Stocks Hitting 52-Week Lows

Financial news for CLRB dated on 2016-03-10: Cellectar Biosciences Reports FY15 EPS \$(7.03) vs. Prior Year Quarter \$(17.53)

Financial news for CLRB dated on 2016-03-04: Cellectar Biosciences Reports 1-for-10 Reverse Stock Split

Financial news for CLRB dated on 2016-01-05: Cellectar Biosciences Says Safety, Activity Data from Phase 1 Trial of CLR 131 in Multiple Myeloma Reviewed, Performance Triggered Advancement Into Second Cohort at Higher Dose

Financial news for CLRB dated on 2015-12-09: Cellectar Biosciences to Give Update on Phase 1 Multiple Myeloma Study In January 2016

Financial news for CLRB dated on 2015-11-24: S-3 from Cellectar Biosciences Shows Registration for 1.5M Shares Common Stock Offering via Selling Holders

Financial news for CLRB dated on 2015-11-12: Cellectar Biosciences Reports Q3 EPS \$(0.25), no estimates

Financial news for CLRB dated on 2015-11-02: Cellectar Biosciences Provides Phospholipid Drug Conjugate (PDC) Platform Development Update

Financial news for CLRB dated on 2015-10-02: Cellectar Biosciences Closes on \$3.3M Financing

Financial news for CLRB dated on 2015-10-01: Cellectar Biosciences Awarded \$2.3M National Cancer Institute Fast-Track SBIR Grant to Advance Phospholipid Drug Conjugate (PDC) Delivery Platform

Financial news for CLRB dated on 2015-08-21: Cellectar Biosciences Introduces Phospholipid Ether-Drug Conjugate (PDC) Platform for Targeted Delivery of Chemotherapeutics

Financial news for CLRB dated on 2015-06-16: Morning Market Gainers

Financial news for CLRB dated on 2015-06-11: Cellectar Biosciences Reports CLR1502 Development Program to be Classified as Combination Product by FDA

Financial news for CLRB dated on 2015-05-21: Cellectar Bioscience Reports Q1 Loss \$0.30, no estimates

Financial news for CLRB dated on 2015-03-24: Cellectar Bioscience Reports FY 2014 -\$1.77, No Estimates Available

Financial news for CLRB dated on 2014-12-04: Cellectar Biosciences Granted Orphan Designation For I-131-CLR1404

Financial news for CLRB dated on 2014-10-15: Cellectar Biosciences Announces Publication of Findings Demonstrating Efficacy of Its Phospholipid Ether Analog Platform in Detecting Colorectal Cancer

Financial news for CLRB dated on 2014-09-04: Cellectar Announces Acceptance Of Investigational New Drug (IND)

Financial news for CLRB dated on 2014-08-20: Cellectar Biosciences Reports Q2 2014 EPS of \$(0.73) Compared To \$(0.72) Q2 2013

Financial news for CLRB dated on 2014-08-20: Cellectar Biosciences Announces Closing Of Public Offering And Partial Exercise Of Underwriter's Over-Allotment Option